CN102475778B - Preparation method for traditional Chinese medicinal composition used for treating essential hypertension - Google Patents
Preparation method for traditional Chinese medicinal composition used for treating essential hypertension Download PDFInfo
- Publication number
- CN102475778B CN102475778B CN201010564295.7A CN201010564295A CN102475778B CN 102475778 B CN102475778 B CN 102475778B CN 201010564295 A CN201010564295 A CN 201010564295A CN 102475778 B CN102475778 B CN 102475778B
- Authority
- CN
- China
- Prior art keywords
- extract
- filter
- add
- parts
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 208000007530 Essential hypertension Diseases 0.000 title claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 121
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 238000002791 soaking Methods 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 15
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- 238000001556 precipitation Methods 0.000 claims abstract description 12
- 239000002244 precipitate Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims abstract description 8
- 244000179560 Prunella vulgaris Species 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 64
- 239000007788 liquid Substances 0.000 claims description 41
- 238000009835 boiling Methods 0.000 claims description 38
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 24
- 244000113306 Monascus purpureus Species 0.000 claims description 22
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 22
- 241000237636 Pheretima Species 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 22
- 229940057059 monascus purpureus Drugs 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 7
- 239000012141 concentrate Substances 0.000 abstract 3
- 238000010438 heat treatment Methods 0.000 abstract 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229940026314 red yeast rice Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 30
- 230000036772 blood pressure Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 239000012567 medical material Substances 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 14
- 230000004872 arterial blood pressure Effects 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 230000007774 longterm Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 241001529739 Prunella <angiosperm> Species 0.000 description 10
- 230000035487 diastolic blood pressure Effects 0.000 description 9
- 238000002481 ethanol extraction Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000035488 systolic blood pressure Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 102000011759 adducin Human genes 0.000 description 6
- 108010076723 adducin Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 electuary Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 3
- 229960002198 irbesartan Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102220099307 rs144750850 Human genes 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000036513 peripheral conductance Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000011706 wistar kyoto rat Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a preparation method for a traditional Chinese medicinal composition used for treating essential hypertension. The preparation method comprises the following steps: soaking rhubarb processed with wine and rhizome coptidis in ethanol, heating the ethanol until the ethanol boils, carrying out extraction and filtration, decocting obtained herb residue with ethanol, carrying out filtration, removing the herb residue and merging two obtained extract so as to prepare extract 1; soaking uncaria, prunella vulgaris and cassia seed with water, heating the water until the water boils, carrying out extraction and filtration, decocting obtained herb residue with water, carrying out filtration, removing the herb residue and merging two obtained extract so as to prepare extract 2; soaking motherwort fruit, lumbricus and red yeast rice with water, heating the water until the water boils, carrying out extraction and filtration, decocting obtained herb residue with water, carrying out filtration, removing the herb residue, merging two obtained extract, carrying out condensation so as to obtain a concentrate, cooling the concentrate, adding ethanol with stirring for alcohol precipitation of the concentrate, carrying out standing and filtration, removing precipitate and condensing obtained filtrate so as to obtain extract 3; uniformly mixing extract 1, extract 2 and extract 3 and condensing mixed extract to prepare fluid extract or dry powder.
Description
Technical field
The present invention relates to a kind of field of medicaments, especially relate to a kind of Chinese medicine composition for the treatment of essential hypertension and preparation method thereof.
background technology
Modern civilization diseases taking metabolism syndrome as representative, closely related with some modern life style, customs etc.Be the high risk factor of type 2 diabetes mellitus and cardiovascular disease, early diagnosis and early intervention metabolism syndrome, contribute to the control of type 2 diabetes mellitus and cardiovascular disease.
The definition of metabolism syndrome, taking central obesity as core, merges blood pressure, blood glucose, triglyceride rising and/or HDL-C and reduces.Wherein relevant central obesity is adopted waistline as diagnosis index.
Hypertension is to increase the clinical syndrome as main manifestations taking systemic arterial pressure, it is modal cardiovascular disease, can be divided into essential hypertension and the large class of secondary hypertension two, most hypertension pathogenies are not clear, are called essential hypertension, account for total hypertensive more than 95%, in the patient of less than 5%, hypertension is a kind of clinical manifestation of some disease, and this,, in the clear and definite and independently cause of disease, is called secondary hypertension.In hypertension prevention and control, exist " three-hypers ", " three is low " phenomenon, three-hypers is that hypertensive sickness rate is high, rate of increase is high, hazardness is high, in China, hypertensive high harm is apoplexy, is secondly heart infarction, renal damage; Three low be that hypertensive awareness is low, treatment rate is low, control rate is low.Within 04 year, announce generaI investigation and show, hypertensive awareness is 30.3%, treatment rate 24.7%, control rate 6.1%.Illustrate that people are to hypertension and hypertensive recognizing dangers wretched insufficiency.
The essential hypertension Chinese patent medicine that antimetabolic syndrome in the market causes is few, and existing medicine a bit belongs to and cures the symptoms, not the disease, and some uses expensive composition, some in application process due to uncertain therapeutic efficacy cut interrupt use.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of essential hypertension.
Another object of the present invention is to provide the preparation method of described Chinese medicine composition.
Compositions of the present invention, made by the Raw material processing of following weight parts:
Radix et Rhizoma Rhei (stir-fried with wine) 3-12 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5-30 part Semen Cassiae 15-60 part
Ramulus Uncariae Cum Uncis 15-60 part Fructus Leonuri 15-60 part Spica Prunellae 22.5-90 part
Pheretima 15-60 part Monas cuspurpureus Went 3-12 part
Compositions of the present invention, preferably made by the Raw material processing of following weight parts:
Radix et Rhizoma Rhei (stir-fried with wine) 5-7 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 10-20 part Semen Cassiae 20-40 part
Ramulus Uncariae Cum Uncis 20-40 part Fructus Leonuri 20-40 part Spica Prunellae 40-50 part
Pheretima 20-40 part Monas cuspurpureus Went 5-7 part
Compositions of the present invention, particularly preferably is by the Raw material processing of following weight parts and makes:
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima
More than, in composition, weight is calculated with crude drug, and part is weight portion, if in grams, above composition can be made into a pharmaceutical preparation 5-50 preparation unit, and described preparation unit refers to, the final drug preparation of making, as make solid preparation 5-50 unit, oral liquid 5-50ml etc.
More than composition can be made into the preparation of 1-6 taking dose, as tablet, makes 18, and each taking dose can be 3-18 sheet, can take 1-6 time altogether.As granule, make 6 bags, each serving using 1-2 bag, can take 3-6 time altogether.
More than composition is by weight as proportioning, in the time producing, can increase or reduce according to corresponding proportion, as large-scale production can be taking kilogram as unit, or taking ton as unit, small-scale production also can be taking milligram as unit, weight can increase or reduce, but the constant rate of raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of amount that can corresponding adjustment composition, increases or reduces being no more than 300%, and drug effect is constant.
More than single medicinal material, especially ministerial drug and the adjuvant drug in composition, also can be replaced by the suitable Chinese medicine with the identical property of medicine, and its drug effect of the Chinese medicine preparation after replacement is constant.
Chinese medicine composition of the present invention is by the raw material of Chinese medicine of above-mentioned formula composition being processed through extraction or other modes, being made pharmaceutically active substance, subsequently, taking this material as raw material, while needs, add medicine acceptable carrier, make according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting respectively raw material of Chinese medicine, also can obtain by common extraction raw material of Chinese medicine, also can obtain by other means, as: by pulverizing, squeeze, calcine, grind, sieve, percolation, extraction, water extraction, alcohol extraction, ester carry, the method such as ketone is carried, chromatography obtains, these active substances can be the material of extractum form, can be that dry extract can be also fluid extract, need to determine to make different concentration according to the difference of preparation.
Pharmaceutically active substance in Chinese medicine composition of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are medicine acceptable carrier.Pharmaceutical composition of the present invention, exists with unit dosage form, and described unit dosage form refers to the unit of preparation, as every of tablet, and every capsules of capsule, every bottle of oral liquid, every bag of granule etc.
Chinese medicine composition of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, preferably peroral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.
Chinese medicine composition of the present invention, the preparation of its oral administration can contain conventional excipient, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet if desired.
Applicable filler comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of suitable medicine comprises sodium lauryl sulphate.
Can, by mixing, fill, the method that tabletting etc. are conventional is prepared solid oral composition.Repeatedly mix and can make active substance be distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid can be for example aqueous or oily suspensions, solution, Emulsion, syrup or elixir, or can be a kind of available water before use or the composite dry products of other suitable carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if need, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this compound can be suspended or dissolve.The preparation of solution, normally by active substance being dissolved in a kind of carrier, being packed into filter-sterilized before a kind of suitable bottle or ampoule, then seals.Adjuvant for example a kind of local anesthetic, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be by freezing this compositions after packing bottle into, and under vacuum, water is removed.
Chinese medicine composition of the present invention, in the time being prepared into medicament, optionally add applicable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Compositions of the present invention is determined usage and dosage according to patient's situation in use, can take every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
The preparation method of the preferred present composition is as follows:
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 5～10 times of 60-95% soak with ethanol 0.5～1h, are heated to, after boiling, extract 1～3h, filter, and medicinal residues add 5～10 times of 60-95% ethanol and decoct 1～3h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Spica Prunellae, Semen Cassiae add 5～10 times of water soaking 0.5～1h, are heated to, after boiling, extract 1～3h, filter, and medicinal residues add 5～10 times of decoctings and boil 1～3h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Fructus Leonuri, Pheretima, Monas cuspurpureus Went add 5～10 times of water soaking 0.5～1h, are heated to, after boiling, extract 1～3h, filter, medicinal residues add 5～10 times of decoctings and boil 1～3h, filter, and medicinal residues discard, extracted twice liquid is merged, and 55～65 DEG C are evaporated to density=1.05-1.20, obtain concentrated solution, be cooled to after room temperature, add 95% ethanol precipitate with ethanol, limit edged stirs, containing alcohol 60～90%, leave standstill 12h to supernatant, filter, precipitation discards, and 55～65 DEG C of concentrating under reduced pressure of filtrate, obtain extracting solution 3.
By extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 DEG C are evaporated to fluid extract (density=1.2～1.4) or dry powder.
The active substance that above technique obtains mixes with medicine acceptable carrier, makes pharmaceutical preparations composition according to galenic pharmacy routine techniques.
The most preferred preparation method of the present invention in an embodiment.
Further illustrate the therapeutic effect of pharmaceutical composition of the present invention by following experiment.
This experiment is the animal drug efficacy study carrying out for compound traditional Chinese medicine, and the animal model of employing is spontaneous hypertension rat model, and route of administration is oral administration gavage, and main observation index is mean arterial pressure (MBP).
Mean arterial pressure (MBP)=cardiac output (CO) × total peripheral vascular resistance (PR).
Experimental section mainly comprises dose-effect, the aging research of four kinds of Chinese medicine preparation blood pressure lowering.
One, materials and methods
(1) experiment material
1, tested material: comprise four kinds of Chinese medicine preparation (CT-1, CT-5, ZF-7, ZY-1), provided by Tianjin Tasly Institute Chinese medicine.Positive drug adopts irbesartan, and (Irbesartan Tablets, France produces, Hangzhou Sanofi-Aventis people's livelihood pharmaceutical Co. Ltd subpackage.Lot number of the repackaged products: 0906193. batch number: 1797. dates of manufacture: 2009.02).
2, laboratory animal: adopt spontaneous hypertension rat (SHR), matched group adopts capital of a country Wistar Kyoto rat (WKY).Purchased from Beijing Vital River Experimental Animals Technology Co., Ltd., the quality certification number: SCXK (capital) 2006-0009.
3, instrument: the non-invasive blood pressure instrument (CODA of Kent company of the U.S.
tM2).
(2) experimental technique
1. experiment grouping: totally six groups: model group, positive drug group, A, B, C, tetra-administration groups of D.Each group is SHR rat, and every group of 6-8 only.
2. dosage design: each kind dosage all calculates according to crude drug amount, obtains following dosage every day.
The design of table 1 dosage
| Group | Sample number into spectrum | Every day is to crude drug amount | Every day is to medicated powder amount | Administration every day | Administration volume |
| A | CT-1 | 39.68g/kg | 3.0g/kg | 2 times | 1ml/100g |
| B | CT-5 | 39.68g/kg | 3.6g/kg | 2 times | 1ml/100g |
| C | ZF-7 | 39.68g/kg | 2.0g/kg | 2 times | 1ml/100g |
| D | ZY-1 | 39.68g/kg | 2.8g/kg | 2 times | 1ml/100g |
| Positive group | Irbesartan | 15.5mg/kg | 1 time | 1ml/100g |
| Model group | Tap water | 1ml/100g |
3, timeliness experiment: animal arrives after laboratory, raises one week in advance, measures basic blood pressure (basic blood pressure need to be measured 1-2 week, guarantees that animal has adapted to instrument, and the blood pressure measuring is true value).According to basic blood pressure random packet.Fasting after grouping, gastric infusion, the animal blood pressure of 0h, 12h, 24h after METHOD FOR CONTINUOUS DETERMINATION administration.Animal starts to carry out long term administration experiment next day after detecting.
4, long-term experiment scheme: animal finishes after single-dose experiment, starts long-term experiment next day, every day gastric infusion, successive administration one month.Measure weekly blood pressure once during this time.And grasp the time, ensure that animal measuring substantially at the same time, avoid in the daytime the impact of self fluctuation of blood pressure.Because animal is more, ensure that consistent (due to twice administration every day, the animal detecting afternoon is just given medicine for the first time in the morning, pulls open delivery time for the time point that detects after every animals administer.The animal that detect the morning, gives medicine for the first time again after having surveyed.Ensure that animal does not pass through fierce struggle before tested).Administration stops administration after one month, after observation drug withdrawal, in convalescent period, the fluctuation situation of blood pressure, detects weekly twice, continues 2-3 week (depending on concrete blood pressure situation).
(3) observation index
1, MAIN OUTCOME MEASURES: blood pressure, comprises systolic pressure, diastolic pressure, mean arterial pressure.
2, other: body weight, heart rate, blood biochemical.
Two, experimental result
1, timeliness experiment
According to experimental result, after single-dose, the blood pressure of each administration group all has certain downward trend.But and model group does not more all have significance to reduce.Heart rate is not found significant change.The results are shown in Table 2,3,4,5
Mean arterial pressure timeliness experiment after table 2 single-dose.mean±SD
Note: and model group comparison in the same time:
* *: p < 0.001
The variation of mean arterial pressure after Fig. 1 single-dose
The time-effect relationship table that the after-contraction of table 3 single-dose is pressed.mean±SD
Note: and model group comparison in the same time:
* *: p < 0.001
The variation that the after-contraction of Fig. 2 single-dose is pressed
The timeliness data of diastolic pressure after table 4 single-dose.mean±SD
Note: and model group comparison in the same time:
* *: p < 0.001
The variation of heart rate after table 5 single-dose.mean±SD
Note: and model group comparison in the same time:
* *: p < 0.001
2, the mean arterial pressure of long term administration experiment changes
According to experimental result, in successive administration one month, the mean arterial pressure that observes weekly each administration group all has certain fluctuation.Administration more all has significance to the mean arterial pressure of the each medicine group of surrounding and model group after two weeks and reduces (p < 0.05).The results are shown in Table 3.
The impact of table 6 long term administration on each treated animal mean arterial pressure.mean±SD
Note: and model group comparison in the same time:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
The variation of a monthly average arterial pressure of Fig. 3 administration.
3, the systolic pressure of long term administration experiment changes
According to experimental result, in successive administration one month, the systolic pressure that observes weekly each administration group all has certain fluctuation.Administration more all has significance to the systolic pressure of the each medicine group of surrounding and model group after two weeks and reduces (p < 0.05).The results are shown in Table 4.
The impact of table 7 long term administration on each treated animal systolic pressure.mean±SD
Note: and model group comparison in the same time:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
The variation that Fig. 4 administration after-contraction in month is pressed.
4, the diastolic pressure of long term administration experiment changes
According to experimental result, in successive administration one month, the diastolic pressure that observes weekly each administration group all has certain fluctuation.Administration more all has significance to the diastolic pressure of the each medicine group of surrounding and model group after two weeks and reduces (p < 0.05).The results are shown in Table 5.
The impact of table 8 long term administration on each treated animal diastolic pressure.mean±SD
Note: and model group comparison in the same time:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
The variation of Fig. 5 administration diastolic pressure after month
5, the changes in heart rate of long term administration experiment
The heart rate of each treated animal all, within normal range, the results are shown in Table 6.
The heart rate impact of table 9 long term administration blood pressure lowering experiment.mean±SD
Note: and model group comparison in the same time:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
6, body weight change during administration.
Each group of spontaneous hypertension rat, a month body weight amount of increase of administration is not very large, increasess slowly.
The impact of table 10 long term administration on each treated animal body weight.mean±SD
Note: and model group comparison in the same time:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
A month the weight of animals of Fig. 6 administration changes
7, administration is after one month, and the blood biochemical of animal changes.
After administration one month, the blood glucose value of each treated animal does not have significant difference.Between each group of ALT, also there is no significant difference, the ALT of CT-1 group has significant reduction (p < 0.05), belongs within the scope of normal physiological.The detection discovery of AST, the AST of positive drug group compares with model group, obviously increases (p < 0.05).The AST of CT-1, CT-5 group compares with model group, significantly reduces (p < 0.05).The testing result of TP (total serum protein) shows, removes ZY-1 group, and the total protein of other each groups is compared with model group, all has and decline significantly (p < 0.001).Sero-abluminous detection discovery, each administration treated animal is compared with model group, and albumin is significantly decline (p < 0.01) all.
Lipids detection, administration one month, the triglyceride of CT-1, CT-5 group, and model more all has reduction (p < 0.01) very significantly.After administration one month, T-CHOL value and the model group of ZY-1 group significantly increase (p < 0.01).But all the other each administration group and model group comparisons, T-CHOL all reduces (p < 0.01) very significantly
Prompting medicine has certain regulating action to Proteometabolism and lipid metabolism.
Table 11 administration is after one month, and the blood biochemical of animal changes (mean ± SD).
Note: and model group comparison:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
Table 12 administration is after one month, and the blood biochemical of animal changes (mean ± SD).
Note: and model group comparison:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
8, convalescent period animal blood pressure testing result
After administration one month, through drug withdrawal one week, positive drug was compared with model group with the systolic pressure of ZF-7 group, still had significance to reduce (p < 0.05), and reduction value > 20mmHg.
After drug withdrawal two weeks, systolic pressure, diastolic pressure and the mean arterial pressure of positive drug, ZF-7 and ZY-1 group, compare with model group, still has significance to reduce (p < 0.05), but reduction value < 20mmHg, does not have biological significance.
After drug withdrawal three weeks, each administration group is compared with model group, does not all have significant difference.
Table 13 administration is after one month, through over recovery one week, and the body weight blood pressure (mean ± SD) of animal.
Note: and model group comparison:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
Table 14 administration is after one month, through over recovery two weeks, and the body weight blood pressure (mean ± SD) of animal.
Note: and model group comparison:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
Table 15 administration is after one month, through over recovery three weeks, and the body weight blood pressure (mean ± SD) of animal.
Note: and model group comparison:
*: p < 0.05;
*: p < 0.01;
* *: p < 0.001
Compositions in the cited all embodiment of the present invention has the essentially identical effect of same embodiment 1-4.
Compositions of the present invention has function and cures mainly: dampness eliminating to alleviate water retention, suppressing the hyperactive liver and subsiding YANG.Be used for the treatment of the diseases such as the essential hypertension that metabolism syndrome causes.Composition stable of the present invention is good, few side effects, long shelf-life, the feature such as therapeutic effect is remarkable.Meanwhile, preparation method of the present invention is simple, is applicable to production, and extraction ratio is high; In this invention, composition prescription is conventional Chinese medicine, avoids the use of rare Chinese medicine and animal drugs, has reduced production cost, benefits extensive patients, is applicable to promoting.
Brief description of the drawings
The variation of mean arterial pressure after Fig. 1 single-dose
The variation that the after-contraction of Fig. 2 single-dose is pressed
The variation of a monthly average arterial pressure of Fig. 3 administration.
The variation that Fig. 4 administration after-contraction in month is pressed.
The variation of Fig. 5 administration diastolic pressure after month
A month the weight of animals of Fig. 6 administration changes
Detailed description of the invention:
Being only to explain content of the present invention by specific embodiment below, is not the further restriction to protection domain of the present invention.
Embodiment 1, pharmaceutical composition of the present invention (CT-1)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), are heated to after boiling slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boils, slow fire boiling 5min, pours out medicinal liquid, and 60～65 DEG C are evaporated to dry.
Embodiment 2, pharmaceutical composition of the present invention (CT-5)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima
Full side adds 8 times of water soaking 0.5h, is heated to, after boiling, extract 1h, filter, medicinal residues add 7 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 DEG C are evaporated to D60=1.05-1.10, obtain concentrated solution, be cooled to after room temperature, add 95% ethanol precipitate with ethanol, limit edged stirs, and containing alcohol 70%, leaves standstill 12h to supernatant, filter, precipitation discards, and 60～65 DEG C of filtrates are evaporated to dry.
The active substance that above technique obtains mixes with medicine acceptable carrier, makes according to galenic pharmacy routine techniques.
Embodiment 3 pharmaceutical composition of the present invention (ZY-1)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima
Radix et Rhizoma Rhei (stir-fried with wine) adds the 50% ethanol extraction 1h of 8 times, filters, and medicinal residues add the 50% ethanol extraction 1h of 8 times, filter, medicinal residues discard, merge extractive liquid,, 60～65 DEG C are evaporated to 4 times of volumes of medical material, are diluted with water to 15 times of volumes of medical material, leave standstill 12h, centrifuging and taking supernatant, D101 purification (medical material amount 1.5 times), loading, washing (5 column volumes), 80% ethanol elution (7 column volumes), 60～65 DEG C of eluents are evaporated to dry.
Prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice adds the 70% ethanol extraction 1h of 8 times, filters, and medicinal residues add the 70% ethanol extraction 1h of 8 times, filter, medicinal residues discard, merge extractive liquid,, and 60～65 DEG C are evaporated to 3 times of volumes of medical material, be cooled to after room temperature, add concentrated hydrochloric acid and regulate pH to 1.5, cold preservation leaves standstill 12h, filters, filtrate discards, and gets precipitation part and is drying to obtain.
All the other flavour of a drug except Radix et Rhizoma Rhei (stir-fried with wine) and prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice, add 8 times of water soaking 0.5h, are heated to, after boiling, extract 1h, filter, medicinal residues add 7 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 DEG C are evaporated to D60=1.05-1.10, obtain concentrated solution, be cooled to after room temperature, add 95% ethanol precipitate with ethanol, limit edged stirs, and containing alcohol 70%, leaves standstill 12h to supernatant, filter, precipitation discards, and 60～65 DEG C of filtrates are evaporated to dry.
In prescription ratio, by above-mentioned three kinds of dry powder blend.
Embodiment 4 pharmaceutical composition of the present invention (ZF-7)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima
Radix et Rhizoma Rhei (stir-fried with wine) and Semen Cassiae add the 50% ethanol extraction 1h of 8 times, filter, and medicinal residues add the 50% ethanol extraction 1h of 8 times, filter, medicinal residues discard, merge extractive liquid,, 60～65 DEG C are evaporated to 4 times of volumes of medical material, are diluted with water to 15 times of volumes of medical material, leave standstill 12h, centrifuging and taking supernatant, D101 purification (medical material amount 1.7 times), loading, washing (5 column volumes), 80% ethanol elution (16 column volumes), 60～65 DEG C of eluents are evaporated to dry.
Prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice adds the 70% ethanol extraction 1h of 8 times, filters, and medicinal residues add the 70% ethanol extraction 1h of 8 times, filter, medicinal residues discard, merge extractive liquid,, and 60～65 DEG C are evaporated to 3 times of volumes of medical material, be cooled to after room temperature, add concentrated hydrochloric acid and regulate pH to 1.5, cold preservation leaves standstill 12h, filters, filtrate discards, and gets precipitation part and is drying to obtain.
Spica Prunellae adds 13 times of water soaking 0.5h, is heated to, after boiling, extract 1h, filter, medicinal residues add 13 times of decoctings and boil 1h, filter, medicinal residues discard, extracted twice liquid is merged, be cooled to after room temperature, D101 purification (medical material 1.5 times), loading, washing (5 column volumes), 80% ethanol elution (medical material 15 times), 60～65 DEG C of eluents are evaporated to dry.
Ramulus Uncariae Cum Uncis and Fructus Leonuri add 9 times of water soaking 0.5h, are heated to, after boiling, extract 1h, filter, medicinal residues add 9 times of decoctings and boil 1h, filter, medicinal residues discard, extracted twice liquid is merged, be cooled to after room temperature, D101 purification (medical material 1.5 times), loading, washing (5 column volumes), 80% ethanol elution (medical material 15 times), 60～65 DEG C of eluents are evaporated to dry.
Pheretima and Monas cuspurpureus Went add 8 times of water soaking 0.5h, are heated to, after boiling, extract 1h, filter, medicinal residues add 7 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 DEG C are evaporated to D60=1.05-1.10, obtain concentrated solution, be cooled to after room temperature, add 95% ethanol precipitate with ethanol, limit edged stirs, and containing alcohol 70%, leaves standstill 12h to supernatant, filter, precipitation discards, and 60～65 DEG C of filtrates are evaporated to dry.
In prescription ratio, by above-mentioned five kinds of dry powder blend.
Embodiment 5 pharmaceutical composition of the present invention
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 8 times of 70% soak with ethanol 1h, are heated to, after boiling, extract 2h, filter, and medicinal residues add 8 times of 70% ethanol and decoct 2h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Spica Prunellae, Semen Cassiae add 8 times of water soaking 1h, are heated to, after boiling, extract 2h, filter, and medicinal residues add 8 times of decoctings and boil 2h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Fructus Leonuri, Pheretima, Monas cuspurpureus Went add 8 times of water soaking 81h, are heated to, after boiling, extract 2h, filter, medicinal residues add 8 times of decoctings and boil 2h, filter, and medicinal residues discard, extracted twice liquid is merged, and 55～65 DEG C are evaporated to density=1.05-1.20, obtain concentrated solution, be cooled to after room temperature, add 80-95% ethanol precipitate with ethanol, limit edged stirs, containing alcohol 60～90%, leave standstill 12-24h to supernatant, filter, precipitation discards, and 55～65 DEG C of concentrating under reduced pressure of filtrate, obtain extracting solution 3.
By extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 DEG C are evaporated to fluid extract (density=1.2～1.4) or dry powder.
Or
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 5 times of 60% soak with ethanol 0.5h, are heated to, after boiling, extract 1h, filter, and medicinal residues add 5 times of 60% ethanol and decoct 1h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Spica Prunellae, Semen Cassiae add 5 times of water soaking 0.5h, are heated to, after boiling, extract 1h, filter, and medicinal residues add 5 times of decoctings and boil 1h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Fructus Leonuri, Pheretima, Monas cuspurpureus Went add 5 times of water soaking 0.5h, are heated to, after boiling, extract 1h, filter, medicinal residues add 5 times of decoctings and boil 1h, filter, and medicinal residues discard, extracted twice liquid is merged, and 55～65 DEG C are evaporated to density=1.05-1.20, obtain concentrated solution, be cooled to after room temperature, add 95% ethanol precipitate with ethanol, limit edged stirs, containing alcohol 60%, leave standstill 12h to supernatant, filter, precipitation discards, and 55～65 DEG C of concentrating under reduced pressure of filtrate, obtain extracting solution 3.
By extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 DEG C are evaporated to fluid extract (density=1.2～1.4) or dry powder.
Or
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 10 times of 95% soak with ethanol 1h, are heated to, after boiling, extract 3h, filter, and medicinal residues add 10 times of 95% ethanol and decoct 3h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Spica Prunellae, Semen Cassiae add 10 times of water soaking 1h, are heated to, after boiling, extract 3h, filter, and medicinal residues add 10 times of decoctings and boil 3h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Fructus Leonuri, Pheretima, Monas cuspurpureus Went add 10 times of water soaking 1h, are heated to, after boiling, extract 3h, filter, medicinal residues add 10 times of decoctings and boil 3h, filter, and medicinal residues discard, extracted twice liquid is merged, and 55～65 DEG C are evaporated to density=1.05-1.20, obtain concentrated solution, be cooled to after room temperature, add 95% ethanol precipitate with ethanol, limit edged stirs, containing alcohol 90%, leave standstill 24h to supernatant, filter, precipitation discards, and 55～65 DEG C of concentrating under reduced pressure of filtrate, obtain extracting solution 3.
By extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 DEG C are evaporated to fluid extract (density=1.2～1.4) or dry powder.
Embodiment 6, granule
Get 100 parts of any one pharmaceutically active substances of embodiment 1-5, add the dextrin of 1.5 times of amounts, 0.5% sucrose, 1.5% microcrystalline Cellulose, makes soft material with appropriate dissolve with ethanol, granulates, and 60 DEG C of forced air dryings, granulate, and granulate, obtains granule.
Embodiment 7, drop pill
Get 100 parts of any one pharmaceutically active substances of embodiment 1-5, add the Polyethylene Glycol of 1000 parts, mix homogeneously, melting, upper pill dripping machine, makes drop pill.
Embodiment 8, oral cavity disintegration tablet
Get 100 parts of any one pharmaceutically active substances of embodiment 1-5, add 5% polyvinylpolypyrrolidone, 0.1% magnesium stearate, 50% microcrystalline Cellulose, make soft material with appropriate alcoholic solution, granulate, 60 DEG C of forced air dryings, granulate, granulate, compacting in flakes, obtains oral cavity disintegration tablet.
Embodiment 9, injectable powder
Get 0.5 part of embodiment 1-5 any one pharmaceutically active substance, 4.5 parts of glucoses, 0.9 part, sodium thiosulfate and distilled water 1ml, after said components mix homogeneously, lyophilization, 500 of subpackages, obtain injectable powder.
Embodiment 10, capsule
Get 100 parts of embodiment 1-5 any one pharmaceutically active substances, add equivalent starch, sucrose and magnesium stearate, granulate, and incapsulates, and obtains capsule.
Embodiment 11, tablet
Get 100 parts of embodiment 1-5 any one pharmaceutically active substances, with starch, sodium carboxymethyl cellulose, Pulvis Talci mix homogeneously, granulate, and tabletting obtains tablet.
Embodiment 12, oral liquid
Get 2 parts of embodiment 1-5 any one pharmaceutically active substances, with 4 parts, syrup, be dissolved in the pure water of 100ml, homogenizing, filters, through high-temperature short-time sterilization (135 DEG C, 4s).Sterile filling, subpackage, make oral liquid.
Embodiment 13, pharmaceutical composition of the present invention
15 parts of 7.5 parts of Semen Cassiaes of 3 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
22.5 parts of 15 parts of Spica Prunellaes of 15 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
3 parts, 15 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), are heated to after boiling slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boils, slow fire boiling 5min, pours out medicinal liquid, and 60～65 DEG C are evaporated to dry.
Embodiment 14, pharmaceutical composition of the present invention
60 parts of 30 parts of Semen Cassiaes of 12 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
90 parts of 60 parts of Spica Prunellaes of 60 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
12 parts, 60 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), are heated to after boiling slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boils, slow fire boiling 5min, pours out medicinal liquid, and 60～65 DEG C are evaporated to dry.
Embodiment 15, pharmaceutical composition of the present invention
20 parts of 10 parts of Semen Cassiaes of 5 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
40 parts of 20 parts of Spica Prunellaes of 20 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
5 parts, 20 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), are heated to after boiling slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boils, slow fire boiling 5min, pours out medicinal liquid, and 60～65 DEG C are evaporated to dry.
Embodiment 16, pharmaceutical composition of the present invention
40 parts of 20 parts of Semen Cassiaes of 7 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
50 parts of 40 parts of Spica Prunellaes of 40 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
7 parts, 40 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), are heated to after boiling slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boils, slow fire boiling 5min, pours out medicinal liquid, and 60～65 DEG C are evaporated to dry.
The active substance that above different process obtains mixes with medicine acceptable carrier, makes pharmaceutical preparations composition according to galenic pharmacy routine techniques; Group component in above-described embodiment can expand or reduce in scale according to need of production simultaneously.
Claims (6)
1. a preparation method for the treatment of the pharmaceutical composition of essential hypertension, is characterized in that, described compositions is processed into by the crude drug process of following weight portion:
Radix et Rhizoma Rhei (stir-fried with wine) 3-12 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5-30 part Semen Cassiae 15-60 part
Ramulus Uncariae Cum Uncis 15-60 part Fructus Leonuri 15-60 part Spica Prunellae 22.5-90 part
Pheretima 15-60 part Monas cuspurpureus Went 3-12 part,
Described preparation method comprises the following steps:
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 5～10 times of 60-95% soak with ethanol 0.5～1h, are heated to, after boiling, extract 1～3h, filter, and medicinal residues add 5～10 times of 60-95% ethanol and decoct 1～3h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1;
Ramulus Uncariae Cum Uncis, Spica Prunellae, Semen Cassiae add 5～10 times of water soaking 0.5～1h, are heated to, after boiling, extract 1～3h, filter, and medicinal residues add 5～10 times of decoctings and boil 1～3h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2;
Fructus Leonuri, Pheretima, Monas cuspurpureus Went add 5～10 times of water soaking 0.5～1h, are heated to, after boiling, extract 1～3h, filter, medicinal residues add 5～10 times of decoctings and boil 1～3h, filter, and medicinal residues discard, extracted twice liquid is merged, and 55～65 DEG C are evaporated to relative density=1.05-1.20, obtain concentrated solution, be cooled to after room temperature, add 80-95% ethanol precipitate with ethanol, limit edged stirs, containing alcohol 60～90%, leave standstill 12-24h to supernatant, filter, precipitation discards, and 55～65 DEG C of concentrating under reduced pressure of filtrate, obtain extracting solution 3;
By extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 DEG C are evaporated to fluid extract or the dry powder of relative density=1.2～1.4, obtain active substance;
The active substance that above technique obtains mixes with medicine acceptable carrier, makes according to galenic pharmacy routine techniques.
2. preparation method according to claim 1, is characterized in that, described compositions is processed into by the crude drug process of following weight portion:
Radix et Rhizoma Rhei (stir-fried with wine) 5-7 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 10-20 part Semen Cassiae 20-40 part
Ramulus Uncariae Cum Uncis 20-40 part Fructus Leonuri 20-40 part Spica Prunellae 40-50 part
Pheretima 20-40 part Monas cuspurpureus Went 5-7 part.
3. preparation method according to claim 2, is characterized in that, described compositions is processed into by the crude drug process of following weight portion:
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts, 30 parts of Monas cuspurpureus Went of Pheretima.
4. according to the preparation method described in claim 1-3 any one, wherein said compositions is any pharmaceutically useful dosage form.
5. preparation method according to claim 4, wherein said compositions is peroral dosage form.
6. preparation method claimed in claim 1, is characterized in that, comprises the following steps:
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 8 times of 70% soak with ethanol 1h, are heated to, after boiling, extract 2h, filter, and medicinal residues add 8 times of 70% ethanol and decoct 2h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1;
Ramulus Uncariae Cum Uncis, Spica Prunellae, Semen Cassiae add 8 times of water soaking 1h, are heated to, after boiling, extract 2h, filter, and medicinal residues add 8 times of decoctings and boil 2h, filter, and medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2;
Fructus Leonuri, Pheretima, Monas cuspurpureus Went add 8 times of water soaking 1h, are heated to, after boiling, extract 2h, filter, medicinal residues add 8 times of decoctings and boil 2h, filter, and medicinal residues discard, extracted twice liquid is merged, and 55～65 DEG C are evaporated to relative density=1.05-1.20, obtain concentrated solution, be cooled to after room temperature, add 80-95% ethanol precipitate with ethanol, limit edged stirs, containing alcohol 60～90%, leave standstill 12-24h to supernatant, filter, precipitation discards, and 55～65 DEG C of concentrating under reduced pressure of filtrate, obtain extracting solution 3;
By extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 DEG C are evaporated to relative density=1.2～1.4 fluid extract or dry powder, obtain active substance;
The active substance that above technique obtains mixes with medicine acceptable carrier, makes according to galenic pharmacy routine techniques.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010564295.7A CN102475778B (en) | 2010-11-29 | 2010-11-29 | Preparation method for traditional Chinese medicinal composition used for treating essential hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010564295.7A CN102475778B (en) | 2010-11-29 | 2010-11-29 | Preparation method for traditional Chinese medicinal composition used for treating essential hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102475778A CN102475778A (en) | 2012-05-30 |
| CN102475778B true CN102475778B (en) | 2014-12-03 |
Family
ID=46088636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010564295.7A Expired - Fee Related CN102475778B (en) | 2010-11-29 | 2010-11-29 | Preparation method for traditional Chinese medicinal composition used for treating essential hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102475778B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1611234A (en) * | 2003-10-29 | 2005-05-04 | 齐娜 | Brain-quieting hypertension-treating medicine, and its preparing method and use |
| CN1657085A (en) * | 2004-09-06 | 2005-08-24 | 青岛国风药业股份有限公司 | Oral Chinese medicinal composition for treating hypertension |
| CN101579480A (en) * | 2008-05-15 | 2009-11-18 | 北京北大维信生物科技有限公司 | Medicinal dripping pill for treating hypertension |
| CN101693062A (en) * | 2009-10-13 | 2010-04-14 | 李隆基 | Health-care product for reducing pressure and sugar and eliminating fat |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258877B2 (en) * | 2001-12-21 | 2007-08-21 | Sunten Phytotech Co., Ltd. | Herbal pharmaceutical composition for treatment of cardiovascular disease |
-
2010
- 2010-11-29 CN CN201010564295.7A patent/CN102475778B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1611234A (en) * | 2003-10-29 | 2005-05-04 | 齐娜 | Brain-quieting hypertension-treating medicine, and its preparing method and use |
| CN1657085A (en) * | 2004-09-06 | 2005-08-24 | 青岛国风药业股份有限公司 | Oral Chinese medicinal composition for treating hypertension |
| CN101579480A (en) * | 2008-05-15 | 2009-11-18 | 北京北大维信生物科技有限公司 | Medicinal dripping pill for treating hypertension |
| CN101693062A (en) * | 2009-10-13 | 2010-04-14 | 李隆基 | Health-care product for reducing pressure and sugar and eliminating fat |
Non-Patent Citations (3)
| Title |
|---|
| 大黄、红曲配伍方案干预颈动脉粥样硬化斑块的临床研究;张莉;《中国优秀硕士学位论文数据库 医药卫生科技辑》;20091115(第11期);第3-33页，尤其是第23页 六、血压、空腹血糖水平比较项下，第3页 （三）治疗方法项下，第32页第4段，第33页第2段 * |
| 张莉.大黄、红曲配伍方案干预颈动脉粥样硬化斑块的临床研究.《中国优秀硕士学位论文数据库 医药卫生科技辑》.2009,(第11期),第3-33页，尤其是第23页 六、血压、空腹血糖水平比较项下，第3页 （三）治疗方法项下，第32页第4段，第33页第2段. * |
| 韩学杰等.茺蔚子 夏枯草.《高血压名家传世灵验药对》.中国医药科技出版社,2010,(第1版),第168页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102475778A (en) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN103083557A (en) | Traditional Chinese medicine composition with functions of reducing blood pressure and blood fat | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN106535912B (en) | Control pharmaceutical composition and its application of human body blood fat and body weight | |
| CN102716283B (en) | Hypolipidemic traditional Chinese medicine | |
| CN103271978A (en) | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness | |
| CN100509009C (en) | A Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and ischemic apoplexy, and its preparation method | |
| CN102670785B (en) | Preparation method of conventional Chinese medicine composition for treating primary hypertension | |
| CN102475778B (en) | Preparation method for traditional Chinese medicinal composition used for treating essential hypertension | |
| CN103520235A (en) | Plant composition with lipid-lowering function and preparation method and application thereof | |
| CN102475780B (en) | Preparation method for traditional Chinese drug composition for treating primary hypertension | |
| CN102475781B (en) | Method for preparing traditional Chinese medicine composition used for treating essential hypertension | |
| CN102475779B (en) | Preparation method of traditional Chinese medicine composition for treating primary hypertension | |
| CN102475782B (en) | Preparation method of traditional Chinese medicinal composition for treating primary hypertension | |
| CN103191221A (en) | Antiobesity effect of hedan preparation | |
| CN102475784B (en) | Chinese medicinal composition for treating essential hypertension and its preparation method | |
| CN102475785B (en) | Preparation method of Chinese medicinal composition for treating essential hypertension | |
| CN102475783B (en) | Preparation method of traditional Chinese medicinal composition for treating primary hypertension | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig | |
| CN101176769B (en) | Pharmaceutical composition of cattail pollen and red orpin | |
| CN106466396B (en) | Gynaecologic menstruation regulating sustained-release dropping pill and preparation method thereof | |
| CN101574454B (en) | Restoration traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141203 Termination date: 20181129 |